Advertisement

Picture EBD Group World of Partnering Opportunities 650x100px

Deals > All

Find below collaborations, license and distribution agreements, grants, investments and loan agreements in Austria, Germany and Switzerland or involving organisations from these countries.

Total search results: 4511 | Ordered by Date (descending)
1 2 3 ... 44 45 46  next pagenext page

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
Merck (DE)–Caris Life Sciences: AI-based drug discovery, 202404– collab strategic up to $1.4b discovery of cancer targets for ADC RnD 2024-04-04
Innocent Meat–Mecklenburg-Vorpommern (govt): investment, 202403 financing round totalling €3m incl €500k from existing investor VC Fonds MV 2024-03-26
Innocent Meat–OTHER: investment, 202403 financing round totalling €3m incl €2.5m from a new private investor 2024-03-26
Innocent Meat–SEVERAL: investment, 202403 financing round €3m with Venture Capital Fonds MV + new private investor 2024-03-26
Protembis–SEVERAL: investment, –202403 financing round Series B €30m completed in two separate capital increases 2024-03-26
Cardior Pharmaceuticals–Novo Group: investment, 202403– acquisition for up to €1.025b incl upfront payment + milestones ANNOUNCED 2024-03-25
Hemotune–SEVERAL: investment, 202403 financing round Series B2 CHF14m led by Belmondo 2024-03-25
Kranus Health–Anaxago: investment, 202403 financing round Series A expansion totalling $5m incl new investor CapHorn 2024-03-25
Kranus Health–Future Positive Capital: investment, 202403 financing round Series A expansion totalling $5m incl new investor Future Positive Capital 2024-03-25
Kranus Health–SEVERAL: investment, 202403 financing round Series A expansion $5m bringing total Series A to $20m 2024-03-25
Volumina Medical–SEVERAL: investment, 202403 financing round Series A $21m with existing + new investors 2024-03-25
Nouscom–Angelini: investment, 202403 investment €7m from Angelini Ventures as Series C extension bringing total round to €75.8m 2024-03-21
Capstan Therapeutics–Bayer: investment, 202403 financing round Series B totalling $175m incl existing + co-investor Leaps by Bayer 2024-03-20
Capstan Therapeutics–Novartis: investment, 202403 financing round Series B totalling $175m incl existing + co-investor Novartis Venture Fund 2024-03-20
Capstan Therapeutics–SEVERAL: investment, 202403 financing round Series B $175m led by RA Capital Management 2024-03-20
Cure51–Hitachi: investment, 202403 seed financing round totalling €15m incl co-investor Hitachi Ventures GmbH 2024-03-20
Cure51–SEVERAL: investment, 202403 seed financing round €15m led by Sofinnova Partners 2024-03-20
Roche–Lonza: investment, 202403– acquisition $1.2b in cash of Genentech biologics manufacturing facility in California from Roche 2024-03-20
Ceban Pharmaceuticals–Medios: investment, 202403– acquisition 100% of Ceban for €235.3m cash + €23.9m in shares from funds managed by Bencis 2024-03-18
Alithea Genomics–Novalis Biotech: investment, 202303 seed financing round extension totalling CHF2.8m incl existing + lead investor Novalis Biotech AF 2024-03-14
Alithea Genomics–SEVERAL: investment, 202303 seed financing round extension CHF2.8m led by Novalis Biotech Acceleration Fund 2024-03-14
Alithea Genomics–TechU Ventures: investment, 202303 seed financing round extension totalling CHF2.8m incl new + co-investor TechU Ventures 2024-03-14
Tubulis–Andera Partners: investment, 202403 financing round Series B2 totalling €128m incl existing + co-investor Andera Partners 2024-03-14
Tubulis–Bavaria (govt): investment, 202403 financing round Series B2 totalling €128m incl existing + co-investor ScaleUp-Fonds Bayern 2024-03-14
Tubulis–BioMedPartners: investment, 202403 financing round Series B2 totalling €128m incl existing + co-investor BioMedPartners 2024-03-14
Tubulis–BPCE: investment, 202403 financing round Series B2 totalling €128m incl existing + co-investor Seventure Partners 2024-03-14
Tubulis–Deep Track Capital: investment, 202403 financing round Series B2 totalling €128m incl new + co-investor Deep Track Capital 2024-03-14
Tubulis–EQT: investment, 202403 financing round Series B2 totalling €128m incl co-lead investor EQT Life Sciences 2024-03-14
Tubulis–Evotec: investment, 202403 financing round Series B2 totalling €128m incl existing + co-investor Evotec 2024-03-14
Tubulis–Frazier: investment, 202403 financing round Series B2 totalling €128m incl new + co-investor Frazier Life Sciences 2024-03-14
Tubulis–Fund+: investment, 202403 financing round Series B2 totalling €128m incl existing + co-investor Fund+ 2024-03-14
Tubulis–Germany (govt): investment, 202403 financing round Series B2 totalling €128m incl existing + co-investor Coparion 2024-03-14
Tubulis–High-Tech Gründerfonds: investment, 202403 financing round Series B2 totalling €128m incl existing + co-investor HTGF 2024-03-14
Tubulis–Nextech: investment, 202403 financing round Series B2 totalling €128m incl co-lead investor Nextech Invest Ltd 2024-03-14
Tubulis–Occident: investment, 202403 financing round Series B2 totalling €128m incl existing + co-investor Occident 2024-03-14
Tubulis–SEVERAL: investment, 202403 financing round Series B2 €128m led by EQT Life Sciences + Nextech Invest 2024-03-14
Mapp Biopharmaceutical–Minapharm: cell line development, 202403– supply service + license €na ProBioGen using GlymaxX for production of MBP091 2024-03-13
Ricoh–ERS Genomics: CRISPR technology, 202001– license non-excl in US + Japan to Ricoh Company 2024-03-13
HiDocTechnologies–Mahana Therapeutics: investment, 202403 acquisition €na of Cara Care by Mahana Therapeutics 2024-03-12
Boehringer–Sosei: GPR52 agonists, 202403– collab drug discovery + excl ww license option €25m upfront + €730m milestones plus tiered royalties 2024-03-11
ProteinDistillery–SEVERAL: investment, 202403 seed financing round €15m (incl credits/grants?) led by Green Generation Fund + Startup Family Office 2024-03-07
Merck (DE)–C4 Therapeutics: protein degraders, 202403– license + collab $16m upfront + $740m milestones + royalties discovery of 2 protein degraders 2024-03-04
BRAIN Biotech–Putsch (Recaro): credit, 202402–202609 convertible bond €5m with MP Beteiligungs-GmbH at 6.52% p.a. 2024-02-29
Cyclize–Aurum Impact: investment, 202402 seed financing round totalling €4.75m incl co-investor Aurum Impact 2024-02-21
Cyclize–High-Tech Gründerfonds: investment, 202402 seed financing round totalling €4.75m incl co-investor HTGF 2024-02-21
Cyclize–OTHER: investment, 202402 seed financing round totalling €4.75m incl high-profile business angels 2024-02-21
Cyclize–PERSON: investment, 202402 seed financing round totalling €4.75m incl business angel Klaus Schäfer 2024-02-21
Cyclize–SEVERAL: investment, 202402 seed financing round €4.75m led by UVC Partners 2024-02-21
Cyclize–TU Munich: investment, 202402 seed financing round totalling €4.75m incl co-investor UnternehmerTUM Funding for Innovators 2024-02-21
Cyclize–UVC Partners: investment, 202402 seed financing round totalling €4.75m incl lead investor UVC Partners 2024-02-21
Waters–Plasmion: ionisation technology, 202402– collab co-marketing/promotion of SICRIT ion source with Waters Acquity QDa + Select Series Cycli IMS 2024-02-21
Firefly Bio–SEVERAL: investment, 202402c emerges with financing round Series A $94m co-led by Versant Ventures + MPM BioImpact 2024-02-15
Firefly Bio–Versant Ventures: investment, 202402c emerges with financing round Series A totalling $94m incl co-lead investor Versant Venture 2024-02-15
Freenome–Roche: investment, 202402 financing round totalling $254m incl existing + lead investor Roche 2024-02-15
Freenome–SEVERAL: investment, 202402 financing round $254m led by Roche 2024-02-15
Sysmex–SAFIA Technologies: mycotoxin immunoassays, 202402– distribution ww of tests for food/agri by Sysmex Partec using SAFIA tech + flow cytometry 2024-02-15
Earlybird–Barmer: investment, 202402 final closing of new Earlybird Health Fund totalling €173m incl investor Barmer 2024-02-14
Earlybird–SEVERAL: investment, 202402 final closing of new Earlybird Health Fund at €173m 2024-02-14
Earlybird–United Kingdom (govt): investment, 202402 final closing of new Earlybird Health Fund totalling €173m incl investor British Patient Capital 2024-02-14
BMS–Roivant: molecular glue degraders, 202402– strategic collab up to $674m discovery of small-molecule molecular glues by VantAI against BMS targets 2024-02-13
CRISPR Therapeutics–EcoR1 Capital: investment, 202402 registered direct offering totalling $280m incl new + co-lead investor EcoR1 Capital 2024-02-13
CRISPR Therapeutics–SEVERAL: investment, 202402 registered direct offering $280m at $71.5/share led by EcoR1 Capital + SR One 2024-02-13
CRISPR Therapeutics–SR One: investment, 202402 registered direct offering totalling $280m incl co-lead investor SR One 2024-02-13
Roche–PathAI: AI-based diagnostics, 202402– collab expansion excl developm of AI-enabled ditial patholoty algorythms for CDx with RTD 2024-02-13
Amply Discovery–SEVERAL: investment, 2024Q2 seed financing round £1.4m PLANNED NOT YET REALISED 2/24 2024-02-12
Amply Discovery–United Kingdom (govt): grant, 202402c grant £835k from Innovate UK + Innosuisse to develop RNAi therapy for AML 2024-02-12
Amply Discovery–United Kingdom (govt): grant, 202402c Innovate UK grant £602k to develop inhaled antimicrobial therapies for MDR lung infections 2024-02-12
Zetta Genomics–Apex Ventures: investment, 202402 2nd seed financing round expansion totalling £1.8m incl existing investor Apex Ventures 2024-02-08
Zetta Genomics–SEVERAL: investment, 202402 2nd seed financing round expansion by £1.8m to total of £3.7m 2024-02-08
Zetta Genomics–Univ Cambridge: investment, 202402 2nd seed financing round expansion totalling £1.8m incl existing investor Univ Cambridge 2024-02-08
Zetta Genomics–Werfen: investment, 202402 2nd seed financing round expansion totalling £1.8m incl new investor We Venture Capital 2024-02-08
Incyte–MorphoSys: tafasitamab, 202402 acquistion ww excl rights by Incyte for $25m for remaining interest in product 2024-02-05
MorphoSys–Novartis: investment, 202402– acquisition of MorphoSys voluntary public takeover offer €2.7b in cash at €68/share 2024-02-05
Silence Therapeutics–Nextech: investment, 202402 private placement totalling $120m incl investor Nextech Invest Ltd 2024-02-05
Silence Therapeutics–SEVERAL: investment, 202402 private placement $120m mit 5.7m ADSs at $12/ADS 2024-02-05
Enterprise Therapeutics–SEVERAL: investment, 202401 financing round Series B follow-on £26m led by Panakès Partners 2024-01-30
TenAces Biosciences–Aion Labs: investment, 202401 founding investor Aion Labs announces TenAces 2024-01-30
Rhineland-Palatinate (govt)–Axa: business park management, 202401– collab of Kadans Science Partner Deutschland + Technologiezentrum Mainz for biotech 2024-01-29
Chemspeed–Bruker: investment, 202401– acquisition €na of Chemspeed Technology AG by Bruker 2024-01-25
BioLizard–MC Services: public relations, 202401 service existent by MC Services 2024-01-23
Disco Pharmaceuticals–AbbVie: investment, 202401 seed financing round totalling €20m incl co-investor AbbVie Ventures 2024-01-16
Disco Pharmaceuticals–Merck (DE): investment, 202401 seed financing round totalling €20m incl co-investor M Ventures 2024-01-16
Disco Pharmaceuticals–Panakés Partners: investment, 202401 seed financing round totalling €20m incl co-investor Panakés Partners 2024-01-16
Disco Pharmaceuticals–SEVERAL: investment, 202401 seed financing round €20m led by Sofinnova Partners 2024-01-16
Disco Pharmaceuticals–Sofinnova: investment, 202401 seed financing round totalling €20m incl lead investor Sofinnova Partners 2024-01-16
BioNTech–WuXi PharmaTech: drug discovery services, 202401– supply discovery of MAb candidates $20m upfront + milestones + royalties by WuXi Biologics 2024-01-11
Calypso Biotech–Novartis: investment, 202401– acquisition $250m upfront + $175m milestones by Novartis SIGNED 2024-01-08
Novartis–Argo Biopharma: RNAi therapeutics, 202401– two license ex-China + collab agreements $185m upfront + $3.98b milestones + royalties 2024-01-07
GlycoEra–BMS: investment, 202401 financing round Series A extension with new investor BMS 2024-01-05
SanReno Therapeutics–Novartis: investment, 202401 acquisition remaining shares by Novartis to become wholly-owend subsidiary 2024-01-05
Full-Life Technologies–OTHER: credit, 202401– loan facility $16m 2024-01-04
Full-Life Technologies–SEVERAL: investment, 202401 financing round Series B $47.3m led by Prosperity7 Ventures + undisclosed healthcare investor 2024-01-04
HI-Bio–SEVERAL: investment, 202401 financing round Series B $95m led by new investor Alpha Wave Global 2024-01-04
Merck (DE)–Inspirna: ompenaclid, 202401– license excl ww ex-US $45m upfront + milestones + royalties 2024-01-04
Nion–Buker: investment, 202401 acquisition €na of Nion by Bruker 2024-01-03
Roche–MediLink Therapeutics: antibody-drug conjugates, 202401– collab + ww license for YL211 $50m upfront + near-term + total nearly $1b + royalties 2024-01-02
Cellbox Solutions–EU (govt): investment, 2024– equity investment up to €10m from EIC Accelerator 2024-01-01
Caresyntax–MTIP: investment, 2023 financing round incl $15m from MTIP II Fund 2023-12-31
Caresyntax–SEVERAL: investment, 2023 financing round with MTIP II + BlackRock + PFM Health Scienes et al 2023-12-31
Planet A Foods–Cherry Ventures: investment, 202312c financing round Series A totalling €15.4m incl co-investor Cherry Ventures 2023-12-31
1 2 3 ... 44 45 46  next pagenext page



Advertisement

Picture Swiss Biotech Association Swiss Biotech Days 2024 SBD24 Basel 650x200px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)


Advertisement

Picture Berlin Partner Top News New Ariceum Radiopharma Lab 650x300px

» top